Back to Search Start Over

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Authors :
Jason Kihyuk Lee
Daniel Ennis
Christian Pagnoux
Source :
Expert opinion on biological therapy. 19(7)
Publication Year :
2019

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by asthma, hypereosinophilia, and progressive multiorgan involvement. Although not fully elucidated, advancement in our understanding of the pathophysiology of EGPA has led to the development of multiple new treatment targets.Herein we review the epidemiology, clinical manifestations, pathophysiology, treatments, and ongoing research in the management of EGPA. The central role of Interleukin-5 (IL-5) in the development and maintenance of hypereosinophilia will be discussed. The value of mepolizumab, an anti-IL-5 monoclonal antibody, in the treatment of EGPA is reviewed in detail.The available literature supports the use of mepolizumab for the induction and maintenance of remission of refractory, relapsing, or glucocorticoid-dependent EGPA with potentially greater benefit in those who are ANCA-positive or those with greater eosinophilia (

Details

ISSN :
17447682
Volume :
19
Issue :
7
Database :
OpenAIRE
Journal :
Expert opinion on biological therapy
Accession number :
edsair.doi.dedup.....735a9c94510d31c95abc02b967255b9f